Clinical Implications of Tisagenlecleucel in B-ALL Treatment: Michael R. Grunwald, MD, FACP

Video

The hematologic oncologist at the Levine Cancer Institute discussed the clinical implications of tisagenlecleucel in the treatment of patients with B-cell acute lymphoblastic leukemia.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Michael R. Grunwald, MD, FACP, clinical assistant professor of medicine, University of North Carolina, and hematologist/ oncologist, Levine Cancer Institute, Atrium Health, about the potential of tisagenlecleucel (Kymriah) in the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL).

Having a CAR T-cell therapy available for the treatment of patients with B-ALL has being exciting, Grunwald says. However, the agent is currently only FDA approved for use in patients up to age 25 years whose disease is refractory or in second or later relapse, Grunwald notes.

Further studies of tisagenlecleucel, as well as similar agents, will be important for older patients with B-ALL because more options are needed in this population, Grunwald continues. For younger patients, however, having this agent available has been significant, as it can get them back into remission. Sometimes patients who receive the agent can experience a very durable remission following relapse, Grunwald concludes.

Related Videos
Leigh Ramos-Platt, MD, on Sharing Experience With Gene Therapy Administration
Daniel Hart, PhD, on CRISPR-Mediated, In Vivo Epigenomic Activation
Luke Roberts, MBBS, PhD, on Developing Gene Therapy for Congestive Heart Failure
PJ Brooks, PhD, on Improved Newborn Screening, Non-Viral Gene Editing: New Frontiers for Neuromuscular Disease
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
© 2024 MJH Life Sciences

All rights reserved.